Importantly, the authors demonstrated in vitro and in vivo that an agonist of SHP2, lovastatin, led to excessive DNA damage and STING pathway activation enhancing the efficacy of irinotecan in preclinical CRC models. This evidence concerns the gene STING1 and colorectal carcinoma.